The study by Wolff et al. therefore identified ADORAs as possible targets for inhibition of HH signaling in BCC, and it is tempting to speculate that other small molecule ADORA agonists currently in clinical or preclinical evaluation may also hold promise for anti-cancer therapy by repressing HH/GLI signaling. Here, GLI1 is linked to skin basal cell carcinoma.